Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

A vaccination to prevent horribly painful shingles may offer an extra benefit: New research suggests it might lower the risk ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

"While the respiratory launches are clearly developing more slowly, we've always expected that it would take time and investment to build them to their full ... signs for GSK in the form of ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analy ...

GSK has teamed up with the University ... changes in cells in precancerous stages that could form the basis of vaccines to prevent full-blown cancer from developing. The pharma group has pledged ...

Nigeria has struggled with raw material dependency, exporting raw materials while importing finished products at exorbitant costs, which has stifled industrialisation and weakened the real sector ...

SCYNEXIS received a $10 million milestone payment from partner GSK in 2024, triggered by the delivery of final ... Research and development expense for the full year ended December 31, 2024 decreased ...

Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...